DOP2023000052A - Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos - Google Patents
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenosInfo
- Publication number
- DOP2023000052A DOP2023000052A DO2023000052A DO2023000052A DOP2023000052A DO P2023000052 A DOP2023000052 A DO P2023000052A DO 2023000052 A DO2023000052 A DO 2023000052A DO 2023000052 A DO2023000052 A DO 2023000052A DO P2023000052 A DOP2023000052 A DO P2023000052A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- compound
- crystalline
- estrogen receptor
- polymorphic forms
- targeted degradation
- Prior art date
Links
- 230000015556 catabolic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 102000015694 estrogen receptors Human genes 0.000 title 1
- 108010038795 estrogen receptors Proteins 0.000 title 1
- TZZDVPMABRWKIZ-XMOGEVODSA-N (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-hydroxy-2-phenyl-1,2,3,4-tetrahydronaphthalen-1-yl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione Chemical compound OC=1C=C2CC[C@@H]([C@@H](C2=CC=1)C1=CC=C(C=C1)N1CCC(CC1)CN1CCN(CC1)C=1C=C2CN(C(C2=CC=1)=O)[C@@H]1C(NC(CC1)=O)=O)C1=CC=CC=C1 TZZDVPMABRWKIZ-XMOGEVODSA-N 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 abstract 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente descripción se refiere a formas polimórficas de (S)-3-(5-(4-((1-(4-((1R,2S)-6-hidroxi-2-fenil-1,2,3,4-tetrahidronaftalen-1-il)fenil)piperidin-4-il)metil)piperazin-1-il)-1-oxoisoindolin-2- il)piperidina-2,6-diona, (Compuesto A), a los métodos de fabricación de estas formas polimórficas y a las composiciones que comprenden estas formas polimórficas. Estas formas polimórficas son útiles en el tratamiento de varias enfermedades, que incluyen, por ejemplo, cáncer de mama.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078225P | 2020-09-14 | 2020-09-14 | |
| PCT/US2021/050046 WO2022056368A1 (en) | 2020-09-14 | 2021-09-13 | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000052A true DOP2023000052A (es) | 2023-07-31 |
Family
ID=78080527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2023000052A DOP2023000052A (es) | 2020-09-14 | 2023-03-14 | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220081416A1 (es) |
| EP (1) | EP4211128A1 (es) |
| JP (1) | JP2023541434A (es) |
| KR (1) | KR20230069144A (es) |
| CN (1) | CN116390916A (es) |
| AR (1) | AR123492A1 (es) |
| AU (1) | AU2021342287A1 (es) |
| BR (1) | BR112023004656A2 (es) |
| CA (1) | CA3194954A1 (es) |
| CL (1) | CL2023000712A1 (es) |
| CO (1) | CO2023004435A2 (es) |
| CR (1) | CR20230162A (es) |
| DO (1) | DOP2023000052A (es) |
| EC (1) | ECSP23027481A (es) |
| IL (1) | IL301155A (es) |
| MX (1) | MX2023002979A (es) |
| PE (1) | PE20231555A1 (es) |
| RS (1) | RS20230288A1 (es) |
| TW (1) | TW202214236A (es) |
| WO (1) | WO2022056368A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117229286A (zh) * | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019011200B1 (pt) | 2016-12-01 | 2021-12-28 | Arvinas Operations, Inc | Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio |
-
2021
- 2021-09-13 US US17/472,847 patent/US20220081416A1/en active Pending
- 2021-09-13 KR KR1020237011950A patent/KR20230069144A/ko active Search and Examination
- 2021-09-13 MX MX2023002979A patent/MX2023002979A/es unknown
- 2021-09-13 TW TW110134024A patent/TW202214236A/zh unknown
- 2021-09-13 BR BR112023004656A patent/BR112023004656A2/pt unknown
- 2021-09-13 JP JP2023516491A patent/JP2023541434A/ja active Pending
- 2021-09-13 AU AU2021342287A patent/AU2021342287A1/en active Pending
- 2021-09-13 AR ARP210102530A patent/AR123492A1/es unknown
- 2021-09-13 CA CA3194954A patent/CA3194954A1/en active Pending
- 2021-09-13 CN CN202180070126.4A patent/CN116390916A/zh active Pending
- 2021-09-13 WO PCT/US2021/050046 patent/WO2022056368A1/en active Application Filing
- 2021-09-13 CR CR20230162A patent/CR20230162A/es unknown
- 2021-09-13 RS RS20230288A patent/RS20230288A1/sr unknown
- 2021-09-13 IL IL301155A patent/IL301155A/en unknown
- 2021-09-13 PE PE2023001149A patent/PE20231555A1/es unknown
- 2021-09-13 EP EP21787193.8A patent/EP4211128A1/en active Pending
-
2023
- 2023-03-13 CL CL2023000712A patent/CL2023000712A1/es unknown
- 2023-03-14 DO DO2023000052A patent/DOP2023000052A/es unknown
- 2023-04-10 CO CONC2023/0004435A patent/CO2023004435A2/es unknown
- 2023-04-14 EC ECSENADI202327481A patent/ECSP23027481A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP23027481A (es) | 2023-07-31 |
| RS20230288A1 (sr) | 2023-06-30 |
| WO2022056368A1 (en) | 2022-03-17 |
| CN116390916A (zh) | 2023-07-04 |
| MX2023002979A (es) | 2023-04-10 |
| PE20231555A1 (es) | 2023-10-03 |
| CR20230162A (es) | 2023-06-02 |
| IL301155A (en) | 2023-05-01 |
| TW202214236A (zh) | 2022-04-16 |
| CA3194954A1 (en) | 2022-03-17 |
| KR20230069144A (ko) | 2023-05-18 |
| AU2021342287A1 (en) | 2023-04-13 |
| US20220081416A1 (en) | 2022-03-17 |
| BR112023004656A2 (pt) | 2023-05-09 |
| CL2023000712A1 (es) | 2023-10-20 |
| EP4211128A1 (en) | 2023-07-19 |
| AR123492A1 (es) | 2022-12-07 |
| CO2023004435A2 (es) | 2023-04-27 |
| JP2023541434A (ja) | 2023-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057222A1 (es) | Agonistas del receptor del neuropeprtido -2 | |
| UY38553A (es) | Inhibidores de cdk2 | |
| NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| UY30292A1 (es) | Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor b(beta)2 adrenérgico | |
| CU23550B7 (es) | Derivados de pirrolo-pirazol sustituidos como inhibidores de quinasa | |
| AR051904A1 (es) | Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| CR20190212A (es) | 1,2,4-triazolonas 2,4,5-trisustituidas | |
| DOP2023000052A (es) | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógenos | |
| ECSP088120A (es) | Derivados de piridazinona como agonistas del receptorde la hormona tiroidea | |
| PE20210373A1 (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar canceres que incluyen los mismos | |
| CR11620A (es) | Derivados de Imadazo-[1,2,b]-Piridazina para el Tratamiento de Enfermedad Mediada por Cinosa de Tirosina C-Met | |
| PE20160521A1 (es) | Inhibidores de autotaxina que comprenden un nucleo ciclico de anillo heteroaromatico-bencil-amida | |
| PE20140171A1 (es) | Pirazoles fungicidas y sus mezclas | |
| CL2008002793A1 (es) | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras | |
| UY29549A1 (es) | Nuevos derivados del fluoreno, composiciones que los contienen y su utilización | |
| UY29177A1 (es) | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos | |
| CU20160183A7 (es) | Sales del clorhidrato de n-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
| CL2021001190A1 (es) | Compuestos de azalactam como inhibidores de hpk1 | |
| CO6460766A2 (es) | Compuestos de haloalquil heteroaril benzamida | |
| CL2023003275A1 (es) | Inhibidores alostéricos de la cromenona de la fosfoinositida 3-quinasa (pi3k) para el tratamiento de enfermedades. | |
| UY30664A1 (es) | Derivados de benzacepin-2(ih)-ona | |
| CL2023000074A1 (es) | Métodos para fabricar un compuesto bifuncional, formas del compuesto bifuncional y formas de dosificación | |
| CL2022000093A1 (es) | Imidazopirimidinas como inhibidores de eed y uso de estas |